InventisBio Co., Limited's (SHSE:688382) Market Cap Dropped CN¥1.1b Last Week; Retail Investors Bore the Brunt
InventisBio Co., Limited's (SHSE:688382) Market Cap Dropped CN¥1.1b Last Week; Retail Investors Bore the Brunt
Key Insights
主要見解
- The considerable ownership by retail investors in InventisBio indicates that they collectively have a greater say in management and business strategy
- A total of 9 investors have a majority stake in the company with 51% ownership
- 14% of InventisBio is held by insiders
- InventisBio中散戶投資者的持股比例相當可觀,表明他們在管理和業務策略上有更大的話語權。
- 共有9個投資者持有該公司的51%所有權
- InventisBio的14%股份由內部人士持有。
To get a sense of who is truly in control of InventisBio Co., Limited (SHSE:688382), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are retail investors with 31% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
要理清InventisBio有限公司(SHSE:688382)真正的控制者,了解其業務的所有權結構是很重要的。而持有最大份額的群體是散戶投資者,持有31%的股份。也就是說,如果股票上漲,這個群體將獲得最大收益(或者在市場下滑時,他們將損失最多)。
As market cap fell to CN¥5.6b last week, retail investors would have faced the highest losses than any other shareholder groups of the company.
隨着市值上週降至56億元,零售投資者將面臨最高的損失,比公司其他任何股東群體都要高。
In the chart below, we zoom in on the different ownership groups of InventisBio.
在下圖中,我們深入探討InventisBio的不同股東群體。

What Does The Institutional Ownership Tell Us About InventisBio?
機構股東對InventisBio的意義是什麼?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。
InventisBio already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see InventisBio's historic earnings and revenue below, but keep in mind there's always more to the story.
InventisBio的股東登記中已經有機構股東。事實上,他們在公司中擁有可觀的股份。這意味着爲這些機構工作的分析師已經關注這隻股票並且對其表示認可。但和其他人一樣,他們也可能犯錯。當多家機構擁有一隻股票時,總是存在一種「擁擠交易」的風險。當這樣的交易出現問題時,多個參與者可能會競相快速賣出股票。在沒有增長曆史的公司中,這種風險更高。您可以在下面看到InventisBio的歷史收益和營業收入,但請記住,故事遠不止於此。

InventisBio is not owned by hedge funds. Our data shows that InventisBio Inc. is the largest shareholder with 19% of shares outstanding. For context, the second largest shareholder holds about 6.3% of the shares outstanding, followed by an ownership of 5.7% by the third-largest shareholder.
InventisBio並不被對沖基金持有。 我們的數據顯示,InventisBio Inc.是最大的股東,持有19%的流通股。 作爲對比,第二大股東持有約6.3%的流通股,第三大股東則持有5.7%。
On further inspection, we found that more than half the company's shares are owned by the top 9 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
進一步調查發現,超過一半的公司股份由前9大股東持有,這表明較大股東的利益在一定程度上被小股東平衡了。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
儘管有必要研究公司的機構持股數據,但研究分析師的情緒也是有道理的,以了解風向。這隻股票有一些分析師的覆蓋,但不多。因此,有提高更多的分析涵蓋面的空間。
Insider Ownership Of InventisBio
InventisBio的內部人持股情況
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
雖然內部人員的精確定義可能具有主觀性,但幾乎所有人都認爲董事會成員是內部人員。管理層最終向董事會負責。然而,如果經理是創始人或CEO,那麼他們成爲執行董事會成員並不罕見。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
Our information suggests that insiders maintain a significant holding in InventisBio Co., Limited. It has a market capitalization of just CN¥5.6b, and insiders have CN¥780m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
我們的信息顯示,內部人員在InventisBio有限公司持有顯著股份。它的市值僅爲CN¥56億,內部人員名下的股份價值爲CN¥78000萬。看到內部人員如此投資於業務真是太好了。值得檢查一下這些內部人員近期是否有買入。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a 31% stake in InventisBio. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
公衆通常是個體投資者,持有InventisBio公司31%的股份。雖然這種所有權規模可能不足以影響政策決策,但他們仍然可以對公司政策產生集體影響。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 6.3% stake in InventisBio. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
股權投資公司在InventisBio中持有6.3%的股份。這表明他們可以在關鍵政策決策中發揮影響力。有些人可能對此感興趣,因爲股權投資有時是積極的,他們要求管理層負責。但有時,股權投資也在出售,已經讓公司上市。
Private Company Ownership
私有公司的所有權
Our data indicates that Private Companies hold 25%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
天齊鋰業零售投資者擁有相當大的股份,表明他們集體在管理和業務策略方面擁有更大的發言權。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for InventisBio you should be aware of.
我覺得了解到底誰擁有一家公司非常有趣。但是要真正獲得洞察,我們還需要考慮其他信息。舉個例子:我們發現InventisBio有一個警告信號,你應該注意。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。